Control of Impurities in the European Pharmacopoeia Principles and update on new developments
|
|
- Martin Norris
- 7 years ago
- Views:
Transcription
1 Control of Impurities in the European Pharmacopoeia Principles and update on new developments Dr. Michael Wierer Deputy Head, European Pharmacopoeia Department, EDQM, Council of Europe
2 Contents 1. Principles of Ph.Eur. impurity control 2. Potentially genotoxic impurities in monographs 3. New methods for mesilate salts etc. 4. New Expression of Acceptance criteria for impurities 2
3 1) Principles of Impurity Control in the European Pharmacopoeia Reflect regulatory practice in monographs Application of ICH guideline Q3A R to pharmacopoeial substances focus on quantitative aspects Adaptation to globalisation constant need for updating Revision of old monographs, in particular progressive replacement of TLC by LC or GC 3
4 Control of Impurities in Substances for Pharmaceutical Use Residual solvents Control is provided by the general monograph Substances for pharmaceutical use and general chapter 5.4 Residual solvents. Inorganic impurities Specific tests in individual monographs Organic impurities Related substances test and/or further tests 4
5 Impurities control - key features Selective related substances tests Limits based on ICH Q3A R Transparency statements Information column brands Correct identification of impurities Meaningful system suitability criteria Separation Sensitivity see chapter 5.10 Control of Impurities 5
6 Standard requirements in an Ph.Eur. monograph Limits for: Specified impurities Unspecified impurities Total impurities Disregard limit Impurities section (transparency list) Specified impurities Other detectable impurities 6
7 Transparency list Bromazepam M. Wierer, 03/12/ EDQM, Council of Europe, All rights reserved
8 Impurities Section Gives impurities that are known to be detected by monograph tests Usually controlled by related substances test, but may be other tests Based on information obtained and verified during elaboration Not necessarily exhaustive 8
9 Specified Impurities are those in specifications for approved products limits based on specifications for approved products and batch analysis data specified impurities are qualified at or above the level indicated in the monograph 9
10 Other Detectable Impurities Unique Ph.Eur. category Impurities sections in monographs may have a list of ODIs Analytical information only: the impurity is detected by the monograph method ODIs are limited in the monograph by the limit for unspecified impurities (or Substances for Pharmaceutical Use) 10
11 General monograph Substances for Pharmaceutical Use (2034) To be read in conjunction with the individual monographs Bridges general requirements to those monographs, which are not yet updated
12 General monograph 2034: Related substances Unless otherwise prescribed, organic impurities in active substances are to be reported, identified wherever possible, and qualified as indicated in Table (general) or in table (for peptides obtained by chemical synthesis) Specific thresholds may be applied for impurities known to be unusually potent or to produce toxic or unexpected pharmacological effects
13 Requirements for active substances except synthetic peptides Use Maximum daily dose Reporting threshold Identification threshold Qualification threshold Human or human and veterinary Human or human and veterinary Veterinary only 2 g /day >0.05 per cent > 2 g/day >0.03 per cent Not applicable >0.10 per cent >0.10 per cent or daily intake >1.0 mg (whichever lower) >0.05 per cent >0.15 per cent or daily intake >1.0 mg (whichever lower) > 0.05 percent 0.20 per cent >0.50 per cent M Wierer, 14/09/ EDQM, Council of Europe, All rights reserved
14 Requirements for peptides obtained by chemical synthesis Reporting threshold Identification threshold Qualification threshold > 0.1 % > 0.5 % > 1.0 % 14
15 Thresholds do not apply for Biological and biotechnological products Peptides (not obtained by chem. synthesis) Oligonucleotides Radiopharmaceuticals Products of fermentation and semisynthetic products derived therefrom Crude products of animal or plant origin or herbal products Excipients
16 Identification of impurities M. Wierer, 03/12/ EDQM, Council of Europe, All rights reserved 15
17 Is retention time a system suitability requirement? Inertsil ODS mm x 4.6 mm, 5µm Kromasil C mm x 4.6 mm, 5µm Alltima C mm x 4.6 mm, 5µm CEFEPIME FOR SST CRS 1
18 Essentials for adequate test application LC methods in the Ph. Eur. originally developed and validated by manufacturers, i.e. well-defined equipment and column(s). Robustness challenged by the fact that only a general description of the column can be given. The chromatographic behaviour with the variety of commercially available C 18 columns is very often too variable, esp. with gradients. need to provide CRS and chromatogram info on the columns used need to set appropriate criteria (SST) M. Wierer, 03/12/ EDQM, Council of Europe, All rights reserved 17
19 Peak identification The identification of a given impurity is needed when the impurity has an individual limit, and/or when a correction factor must be applied. In all the other cases although desirable, the identification is not required. The method of choice to identify an impurity in a chromatogram is by comparison with an authentic sample. M. Wierer, 03/12/ EDQM, Council of Europe, All rights reserved 18
20 CF CF Example : Torasemide for system suitability CRS Rs Specified impurities: A, B, C, D. 20
21 Ph. Eur. Reference Substances Use of the isolated impurity as impurity CRS CONSTRAINT: often impurities are available in scarce quantities only CRS: a sample containing the impurity of interest (a bad batch, a spiked batch, a mixture of substance and its impurities). M. Wierer, 03/12/ EDQM, Council of Europe, All rights reserved 20
22 Description of HPLC columns: Example: Amiodarone HCl reversed phase LC elution, UV detection Column: _ size: l =0.15 m, Ø = 4.6 mm _ stationary phase: octadecylsilyl silica gel for chrom. (5µm) _ temperature: 30 C What you will find in the monograph: dimensions, type of stationary phase, particle size Not given: brand names of columns 22
23 EDQM Knowledge database contains information on - Reference standards - Column or reagent brand names 23
24 Column ranking/classification systems available on the internet columnclassification
25 System Suitability criteria: Limits to ensure adequate test performance Resolution of two closely eluting peaks (critical peak pair) Peak-to-valley ratio (incomplete separation, peaks of very different size) Similarity or concordance with a chromatogram supplied Signal to noise ratio for sensitivity M. Wierer, 03/12/ EDQM, Council of Europe, All rights reserved 24
26 Sumatriptan impurity mixture CRS (spiked samples) - resolution imp C / sumatriptan minimum clearly separated peaks M. Wierer, 03/12/ EDQM, Council of Europe, All rights reserved 25
27 Peak-to-valley ratio M. Wierer, 03/12/ EDQM, Council of Europe, All rights reserved 26
28 Example: Anhydrous paroxetine Signal-to-noise ratio Min. 3 for the peak due impurity H in ref. solution (e). = 0.05% M. Wierer, 03/12/ EDQM, Council of Europe, All rights reserved 27
29 Why are revisions needed? M. Wierer, 03/12/ EDQM, Council of Europe, All rights reserved 28
30 Revision Needs Replace TLC by LC, GC or CZE Add a limit for total of impurities Allow unambiguous peak identification Bring general acceptance criterion in line with Substances for pharmaceutical use Introduce impurity section (transparency list) Updates for new active substance sources 30
31 Special revision programme: Example Norfloxacin TLC: max. 3 spots, each <= 0.2%, now replaced by LC: 31
32 2) Potentially genotoxic impurities in monographs CHMP Guideline on the limits of genotoxic impurities in effect CPMP/SWP/5199/02, EMEA/CHMP/QWP/251344/2006 Applicable to New active substances New applications of existing active substances unless there is assurance that no new or higher levels are introduced as compared to products currently authorised in EU 32
33 Problem statement What about existing substances covered by an EP monographs? Transparency lists may contain structures of potentially genotoxic substances Structural alert does not automatically imply genotoxicity Sometimes production section to flag up PGIs 33
34 PGIs in transparency statements (1) Classified as «other detectable impurities» This in analytical information only This does not necessarily confirm the occurrence of the impurity at relevant levels Rarely adequate control of such substances EP monographs may relate to several routes of synthesis The PGI may be irrelevant for certain routes of synthesis 34
35 PGIs in transparency statements (2) Introduction of regular testing would not be helpful in many cases Analytical challenge: sensitivity, specificity Problem for authors of monograph revisions, new monographs and users Policy paper for European Pharmacopoeia Commission has been adopted after consultation of EMA QWP and SWP es_pheur_monographs.pdf 35
36 Basic principle of the policy For substances uses in human or human and veterinary products: Folllow the approach of the CHMP guideline For substances solely used in vet. products: case-by case guidance by comp. authorities 36
37 Case 1 Substance included in a medicinal product authorised after application of the CHMP guideline* Monograph should be based on marketing authorization(s) 37
38 Case 2 Substance included in a medicinal product authorised before application of the CHMP guideline*: no PGI expected from synthetic route. No action needed, monograph based on marketing authorization 38
39 Case 3 Substance included in a medicinal product authorised before application of the CHMP guideline*: PGI expected from synthetic route of first authorised product and subsequently authorised products (if any) have no expected PGI or same PGI as the first authorised product at same or lower level and no data showing genotoxicity. No action needed during elaboration of monograph (based on marketing authorization), no revision of existing monographs 39
40 Case 4 Substance included in a medicinal product authorised before application of the CHMP guideline*: PGI expected from synthetic route of an authorised product and data showing genotoxicity of an expected PGI. Monograph should be elaborated or revised based on evaluation by the Competent Authority. 40
41 Case 5 Substance included in a medicinal product authorised before application of the CHMP guideline*: PGI expected from synthetic route of first authorised product, and subsequently authorised products have a new expected PGI or same PGI as innovator product at a higher level and data showing genotoxicity of an expected PGI. Monograph should be elaborated or revised based on evaluation of new PGI or high level of previously known PGI by the Competent Authority 41
42 Consquences Monographs (limit and tests) will be updated if relevant information is submitted from stakeholders (in particular National Competent Authorities) The existence/use of a monograph does not release the user from his responsibility to review the synthetic route, the process control and the impurity profile as regards PGIs Certification Unit will apply the Guideline and Regulatory guidance 42
43 3) Update on methods concerning Mesilates Methanesulfonic acid C H 3 O S O Sources: O H + R-OH by-product impurities R= Methyl, Ethyl, Isopropyl Alkylated Agents Mesilates (Esters) C H 3 O S O O HR Potentially genotoxic!
44 Overview of methods developed Determination of methansulfonyl chloride in methanesulfonic acid (Pharmeuropa 22.3) Methyl, ethyl and isopropyl methanesulfonate in methanesulfonic acid (Ph. Eur. 7.1); Determination of methyl, ethyl and isopropyl methanesulfonate in active substances (adopted, supplement 7.3) 44
45 Determination of Methyl-, Ethyl- and Isopropyl- methanesulfonate in active substance mesilates General method has been validated for the determination of methyl, ethyl and isopropyl esters of methanesulfonic acid ( in concentrations between 0.1 ppm and 5 ppm) for Betahistine mesilate Method has been examined for 10 further mesilate APIs described in Ph. Eur. Solutions need to be adapted to target concentrations and validated by the user 45
46 Method principle: Dissolution of the mesilate API in H 2 O/ Acetonitrile Derivatisation of MMS, EMS and IprMS with NaI and Na 2 S 2 O 3 to the respective iodide derivatives Headspace-GC with MS detection / SIM mode Internal standard Butylmethanesulphonate 1 Methyl- 2 EthyI- 3 Isopropyl- 4 Butyliodide 46
47 Monograph title Limit calculated based on maximum daily dose and TTC (ppm) Lower concentration tested during method verification (ppm) Betahistine mesilate 42 5 Bromocriptine mesilate 25 2 Codergocrine mesilate Deferoxamine mesilate Dihydroergocristine mesilate Dihydroergotamine mesilate Doxazosin mesilate Pefloxacin mesilate dihydrate Pergolide mesilate Phentolamine mesilate Saquinavir mesilate
48 4) New Expression of Acceptance Criteria in the Test for Related Substances
49 Acceptance Criteria in the Test for Related Substances limit test style So far usually expressed in terms of comparison of peak areas: Not more than the area of the principal peak in the chromatogram with the reference solution... Pass/fail result (limit test) not a true quantitative (numerical) test result
50 Reasons for the proposed change to new ( quantitative ) style Related substances tests were aligned with ICH Q3R and VICH GL 10 requirements Users have requested a format more adapted to quantitative purposes and to industrial practice of calculating/reporting results 50
51 Proposed change ( quantitative style) Calculate the percentage content of impurity X from the concentration of reference solution... Numerical result for each impurity Total of impurities can directly be calculated rather than summing up areas or corrected areas Use of term reporting threshold
52 Current status Numerous (mostly positive) comments received Agreed by Chairs of Chemical Expert Groups Due to the large impact o o o o No retrospective application Use for new and revised texts via Pharmeuropa General Notices, Chapter 5.10 to be amended to take account of limit test style and quantitative style Adoption at Ph.Eur. Commission 3/2011 expected 52
53 Conclusion Impurity control is the key item in Ph.Eur. active substance monographs Related substances TLC tests are replaced by LC or GC test (spec. revision programme) Ph.Eur. is updating old monographs whereever possible but ongoing New challenge: control of genotoxic impurities New methods for control of mesilates elaborated Style for impurity acceptance criteria now aligned with ICH Q3AR2 and VICH GL 10 53
54 Thank you! 54
IMPURITIES IN NEW DRUG PRODUCTS
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE IMPURITIES IN NEW DRUG PRODUCTS Q3B(R2) Current
More informationVALIDATION OF ANALYTICAL PROCEDURES: TEXT AND METHODOLOGY Q2(R1)
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE VALIDATION OF ANALYTICAL PROCEDURES: TEXT AND METHODOLOGY
More informationLUMEFANTRINE Draft proposal for The International Pharmacopoeia (October 2006)
October 2006 RESTRICTED LUMEFANTRINE Draft proposal for The International Pharmacopoeia (October 2006) DRAFT FOR DISCUSSION World Health Organization 2006 All rights reserved. This draft is intended for
More informationImpurity Profiles in Active Pharmaceutical Ingredients
Impurity Profiles in Active Pharmaceutical Ingredients EU/Swissmedic GMP Workshop Beijing University, Sept. 20 22, 2006 Dr. Susanne Keitel Federal Institute for Drugs and Medical Devices (BfArM), Germany
More informationICH Topic Q 2 (R1) Validation of Analytical Procedures: Text and Methodology. Step 5
European Medicines Agency June 1995 CPMP/ICH/381/95 ICH Topic Q 2 (R1) Validation of Analytical Procedures: Text and Methodology Step 5 NOTE FOR GUIDANCE ON VALIDATION OF ANALYTICAL PROCEDURES: TEXT AND
More informationImplementing New USP Chapters for Analytical Method Validation
Implementing New USP Chapters for Analytical Method Validation March 2010 Ludwig Huber Fax.: +49 7243 602 501 E-mail: Ludwig_Huber@labcompliance.com Today s Agenda Handling Method Changes vs. Adjustments
More informationGuidance for Industry
Guidance for Industry Q2B Validation of Analytical Procedures: Methodology November 1996 ICH Guidance for Industry Q2B Validation of Analytical Procedures: Methodology Additional copies are available from:
More informationEDQM: 50 YEARS OF LEADERSHIP IN THE QUALITY OF MEDICINES PAVING THE WAY FOR THE FUTURE
EDQM: 50 YEARS OF LEADERSHIP IN THE QUALITY OF MEDICINES PAVING THE WAY FOR THE FUTURE 6-8 October 2014 Strasbourg, France WORKSHOP IMPURITIES 1 Workshop Session IMPURITIES DNA-reactive impurities: An
More informationTYPICAL FDA COMMENTS ON IMPURITY PROFILING IN CTD/CEP/DMF SUBMISSIONS
TYPICAL FDA COMMENTS ON IMPURITY PROFILING IN CTD/CEP/DMF SUBMISSIONS By Rajkumar Gupta, Managing Director Perfect Pharmaceutical Consultant Pvt. Ltd and Director Global Institute of Regulatory affairs,
More informationGUIDELINES FOR THE VALIDATION OF ANALYTICAL METHODS FOR ACTIVE CONSTITUENT, AGRICULTURAL AND VETERINARY CHEMICAL PRODUCTS.
GUIDELINES FOR THE VALIDATION OF ANALYTICAL METHODS FOR ACTIVE CONSTITUENT, AGRICULTURAL AND VETERINARY CHEMICAL PRODUCTS October 2004 APVMA PO Box E240 KINGSTON 2604 AUSTRALIA http://www.apvma.gov.au
More informationANALYTICAL METHODS INTERNATIONAL QUALITY SYSTEMS
VALIDATION OF ANALYTICAL METHODS 1 GERT BEUVING INTERNATIONAL PHARMACEUTICAL OPERATIONS TASKS: - Internal auditing - Auditing of suppliers and contract manufacturers - Preparing for and guiding of external
More informationOMCL Network of the Council of Europe QUALITY MANAGEMENT DOCUMENT
OMCL Network of the Council of Europe QUALITY MANAGEMENT DOCUMENT PA/PH/OMCL (11) 204 3R HANDLING AND USE OF REFERENCE STANDARDS IN THE OMCL NETWORK Full document title and reference Document type Legislative
More informationPHARMACEUTICAL REFERENCE STANDARDS
PHARMACEUTICAL REFERENCE STANDARDS 11 th International Symposium organised by the European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe 3-4 September 2012, Strasbourg,
More information1. Name of pharmacopoeia
1 1. Name of pharmacopoeia European Pharmacopoeia 36 Member states (Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece,
More informationStep-by-Step Analytical Methods Validation and Protocol in the Quality System Compliance Industry
Step-by-Step Analytical Methods Validation and Protocol in the Quality System Compliance Industry BY GHULAM A. SHABIR Introduction Methods Validation: Establishing documented evidence that provides a high
More informationDRAFT MONOGRAPH FOR THE INTERNATIONAL PHARMACOPOEIA PARACETAMOL ORAL SUSPENSION (September 2010)
September 2010 RESTRICTED DRAFT MONOGRAPH FOR THE INTERNATIONAL PHARMACOPOEIA PARACETAMOL ORAL SUSPENSION (September 2010) DRAFT FOR COMMENTS This document was provided by a quality control expert and
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS (CVMP)
European Medicines Agency Veterinary Medicines and Inspections London, 15 April 2005 EMEA/CVMP/134/02 Rev 1 CPMP/QWP/227/02 Rev 1 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) COMMITTEE FOR VETERINARY
More informationRapid Pharma Development GmbH. Impurities in the contexts of CMC Development
Rapid Pharma Development GmbH Impurities in the contexts of CMC Development The Challenge What is your Goal? What is your path? Plan for Success Define your goal: Target Product Profile Daily dosage Cost
More informationSPECIFICATIONS AND CONTROL TESTS ON THE FINISHED PRODUCT
SPECIFICATIONS AND CONTROL TESTS ON THE FINISHED PRODUCT Guideline Title Specifications and Control Tests on the Finished Product Legislative basis Directive 75/318/EEC as amended Date of first adoption
More informationImporting pharmaceutical products to China
Importing pharmaceutical products to China Imported pharmaceutical products need pre-market approval before entering the Chinese market Imported drugs for human use are required to obtain pre-market approval
More informationQUESTIONS AND ANSWERS ABOUT THE EDQM ACTIVITIES
QUESTIONS AND ANSWERS ABOUT THE EDQM ACTIVITIES Why are Pharmacopoeias so important in a globalised world? Pharmacopoeias have historically provided collections of medical recipes intended to ensure accurate
More informationSIMULTANEOUS DETERMINATION OF TELMISARTAN AND HYDROCHLOROTHIAZIDE IN TABLET DOSAGE FORM USING REVERSE PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY
CHAPTER 5 SIMULTANEOUS DETERMINATION OF TELMISARTAN AND HYDROCHLOROTHIAZIDE IN TABLET DOSAGE FORM USING REVERSE PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY CHAPTER 5 Simultaneous determination of Telmisartan
More informationGuideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1)
22 May 2014 EMA/CHMP/BWP/247713/2012 Committee for Medicinal Products for Human Use (CHMP) Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance:
More informationRegulatory Expectations for GMP: What s Happening. Patricia Weideman, PhD Director, Product Quality & Occupational Toxicology Genentech, Inc.
Regulatory Expectations for GMP: What s Happening Patricia Weideman, PhD Director, Product Quality & Occupational Toxicology Genentech, Inc. Topics Background for changes and expectations of regulatory
More informationGuideline on dossier requirements for Type IA and IB notifications
Guideline on dossier requirements for Type IA and IB notifications In accordance with Regulation (EC) No 726/2004 and Directives 2001/83/EC and 2001/82/EC, a common approach to the procedures for variations
More informationSession 6: WHO Prequalification Programme. Key Process Steps WHO: Medicines UNFPA: Condoms and IUDs
Session 6: WHO Prequalification Programme Key Process Steps WHO: Medicines UNFPA: Condoms and IUDs Session adapted from the WHO training workshop on prequalification and the WHO technical briefing seminar
More informationGuideline on stability testing for applications for variations to a marketing authorisation
21 March 2014 EMA/CHMP/CVMP/QWP/441071/2011- Rev.2 Committee for Medicinal Products for Human Use (CHMP)/ Committee for Medicinal Products for Veterinary Use (CVMP) Guideline on stability testing for applications
More informationInternational GMP Requirements for Quality Control Laboratories and Recomendations for Implementation
International GMP Requirements for Quality Control Laboratories and Recomendations for Implementation Ludwig Huber, Ph.D. ludwig_huber@labcompliance.com Overview GMP requirements for Quality Control laboratories
More informationAnnex 6. Guidance on variations to a prequalified product dossier. Preface
Annex 6 Guidance on variations to a prequalified product dossier Preface This guidance document was technically and structurally inspired by the Guideline on dossier requirements for type IA and IB notifi
More informationWhat s New with Impurities in Pharmaceuticals?
What s New with Impurities in Pharmaceuticals? Southern California Pharmaceutical Discussion Group January 15, 2015 Bernard A. Olsen, Ph.D Olsen Pharmaceutical Consulting, LLC bolsen@comcast.net ICH Q3
More informationGuide to Reverse Phase SpinColumns Chromatography for Sample Prep
Guide to Reverse Phase SpinColumns Chromatography for Sample Prep www.harvardapparatus.com Contents Introduction...2-3 Modes of Separation...4-6 Spin Column Efficiency...7-8 Fast Protein Analysis...9 Specifications...10
More informationControl Strategy Case Studies
Control Strategy Case Studies Vance Novack, GSK Workshop on Implementation of ICH Q8/Q9/Q10 and Other Quality Guidelines Beijing, China, Dec 2008 Control Strategy Case Studies The information and knowledge
More informationPublic Assessment Report. Scientific discussion. Calcium and Vitamine D3 Alpex 1000 mg/880 IE, effervescent granules
Public Assessment Report Scientific discussion Calcium and Vitamine D3 Alpex 1000 mg/880 IE, effervescent granules (calcium carbonate and cholecalciferol) NL License RVG: 111783 Date: 12 March 2015 This
More informationAspects of industrial purification of peptides using large-scale chromatography. Lars Andersson and Jonas Persson
Aspects of industrial purification of peptides using large-scale chromatography Introduction By Lars Andersson and Jonas Persson PolyPeptide Laboratories (Sweden) AB PO Box 30089 SE-200 61 LIMHAMN SWEDEN
More informationASSESSMENT AND CONTROL OF DNA REACTIVE (MUTAGENIC) IMPURITIES IN PHARMACEUTICALS TO LIMIT POTENTIAL CARCINOGENIC RISK
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE ASSESSMENT AND CONTROL OF DNA REACTIVE (MUTAGENIC)
More informationWorking with ICH Quality Guidelines - the Canadian Perspective
Working with ICH Quality Guidelines the Canadian Perspective Krishnan Tirunellai, Ph. D. Bureau of Pharmaceutical Sciences Therapeutic Products Directorate Health Canada December 3, 2008 Outline Introduction
More informationGUIDELINE ON ACTIVE PHARMACEUTICAL INGREDIENT MASTER FILE (APIMF) PROCEDURE 1 (The APIMF procedure guideline does not apply to biological APIs.
15 January 2007 GUIDELINE ON ACTIVE PHARMACEUTICAL INGREDIENT MASTER FILE (APIMF) PROCEDURE 1 (The APIMF procedure guideline does not apply to biological APIs.) TABLE OF CONTENTS 1 INTRODUCTION... 2 2
More informationICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological/ biological entities)
November 2012 EMA/CHMP/ICH/425213/2011 ICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological/ biological entities) Step 5 Transmission to CHMP May
More informationCleaning Validation in Active pharmaceutical Ingredient manufacturing plants
Cleaning Validation in Active pharmaceutical Ingredient manufacturing plants September 1999 Table of contents 1. Foreword...... 2 2. Objective...... 3 3. Scope........ 4 4. Potential residues... 5 5. Current
More informationGuide to Using. Public web application for searching and consulting the cosmetic ingredient and substance database. Last updated on 12 March 2009.
Guide to Using Public web application for searching and consulting the cosmetic ingredient and substance database Last updated on 12 March 2009. Contents Introduction 2 Overview...2 Disclaimer...3 Application
More informationDrug Information Journal, Vol. 33, pp. 755 761, 1999 0092-8615/99
Drug Information Journal, Vol. 33, pp. 755 761, 1999 0092-8615/99 Printed in the USA. All rights reserved. Copyright 1999 Drug Information Association Inc. THE ACTIVE PHARMACEUTICAL INGREDIENTS STARTING
More informationAnalysis of the Vitamin B Complex in Infant Formula Samples by LC-MS/MS
Analysis of the Vitamin B Complex in Infant Formula Samples by LC-MS/MS Stephen Lock 1 and Matthew Noestheden 2 1 AB SCIEX Warrington, Cheshire (UK), 2 AB SCIEX Concord, Ontario (Canada) Overview A rapid,
More informationApplication Note. Determination of Nitrite and Nitrate in Fruit Juices by UV Detection. Summary. Introduction. Experimental Sample Preparation
Application Note Determination of Nitrite and Nitrate in Fruit Juices by UV Detection Category Food Matrix Fruit Juice Method HPLC Keywords Ion pair chromatography, fruit juice, inorganic anions AZURA
More informationIntelligent use of Relative Response Factors in Gas Chromatography-Flame Ionisation Detection
52 May/June 2012 Intelligent use of Relative Response Factors in Gas Chromatography-Flame Ionisation Detection by Karen Rome and Allyson McIntyre, AstraZeneca, Macclesfield, SK10 2NA, UK Quantitative analysis
More informationTraining Courses 2014 HPLC GC SPE
Training Courses 2014 HPLC GC SPE 2 1 3 5 4 6 7 5 10 15 20 min 8 2 Courses & Presenters HPLC How to Run HPLC Methods Price: 249 + VAT Code: SS0-5943 Page: 4 How to Develop HPLC Methods Price: 249 + VAT
More informationApplications of Organic Solvent Nanofiltration in the Process Development of Active Pharmaceutical Ingredients. Dominic Ormerod
Applications of rganic Solvent Nanofiltration in the Process Development of Active Pharmaceutical Ingredients Dominic rmerod Introduction A non-thermal solvent exchange. Removal of Excess reagents via
More informationComparative analysis between the possible regulatory approaches to GMP compliance TITOLO PRESENTAZIONE
Comparative analysis between the possible regulatory approaches to GMP compliance TITOLO PRESENTAZIONE Dr. Fulvio CARLOTTI, GNOSIS SpA, Corporate QA Director September 26, 2014 Scope of GMP GMP compliance
More informationGuideline on Process Validation
1 2 3 4 29 March 2012 EMA/CHMP/CVMP/QWP/70278/2012-Rev1 Committee for Medicinal Products for Human Use (CHMP) Committee for Medicinal Products for Veterinary Use (CVMP) 5 6 Draft Draft Agreed by CHMP /
More informationCleaning validation of cleanrooms and preparation equipments
Cleaning validation of cleanrooms and preparation equipments Head of production Central Pharmacy, Geneva University Hospitals EAHP Foundation Seminar: Patient Safety; More About Compounding" 23-25 May,
More informationPurification of reaction mixtures using flash chromatography.
Purification of reaction mixtures using flash chromatography. This technical note details the use of ISOLUTE Flash chromatography columns for the purification of reaction mixtures. What is flash chromatography?
More informationThe Theory of HPLC. Gradient HPLC
The Theory of HPLC Gradient HPLC i Wherever you see this symbol, it is important to access the on-line course as there is interactive material that cannot be fully shown in this reference manual. Aims
More informationQuality by Design Approach for the Separation of Naproxcinod and its Related Substances by Fused Core Particle Technology Column
Journal of Chromatographic Science Advance Access published October 11, 2012 Journal of Chromatographic Science 2012;00:1 7 doi:10.1093/chromsci/bms162 Article Quality by Design Approach for the Separation
More informationThe Essential CHROMacademy Guide. Mobile Phase Optimization Strategies for Reversed Phase HPLC
The Essential CHROMacademy Guide Mobile Phase Optimization Strategies for Reversed Phase HPLC Webcast Notes Type your questions in the Submit Question box, located below the slide window You can enlarge
More information1.1 This test method covers the qualitative and quantitative determination of the content of benzene and toluene in hydrocarbon wax.
Standard Method for Analysis of Benzene and Toluene Content in Hydrocarbon Waxes by Headspace Gas Chromatography EWF METHOD 002/03 (Version 1 Reviewed 2015) 1 Scope 1.1 This test method covers the qualitative
More informationEDQM: 50 YEARS OF LEADERSHIP IN THE QUALITY OF MEDICINES PAVING THE WAY FOR THE FUTURE
1 EDQM: 50 YEARS OF LEADERSHIP IN THE QUALITY OF MEDICINES PAVING THE WAY FOR THE FUTURE 6-8 October 2014 Strasbourg, France WORKSHOP FINISHED PRODUCT MONOGRAPHS 1 2 Finished Product Pilot Project - Background
More informationDetection of Estrogens in Aqueous and Solid Environmental Matrices by Direct Injection LC-MS/MS
Detection of Estrogens in Aqueous and Solid Environmental Matrices by Direct Injection LC-MS/MS D. Loeffler 1, M. Ramil 1, T. Ternes 1, M. Suter 2, R. Schönenberger 2, H.-R. Aerni 2, S, König, A. Besa,
More informationHow To Test For Contamination In Large Volume Water
Automated Solid Phase Extraction (SPE) of EPA Method 1694 for Pharmaceuticals and Personal Care Products in Large Volume Water Samples Keywords Application Note ENV0212 This collaboration study was performed
More informationEUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. EudraLex. The Rules Governing Medicinal Products in the European Union
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health systems and products Medicinal products- authorisations, European Medicines Agency Brussels, EudraLex The Rules Governing Medicinal
More informationHighly Potent APIs The right platform, people and procedures for successful development and manufacturing
Pharma&Biotech Highly Potent APIs The right platform, people and procedures for successful development and manufacturing Custom Manufacturing and Development Services for Highly Potent APIs Pharma&Biotech
More informationDesign of Experiments for Analytical Method Development and Validation
Design of Experiments for Analytical Method Development and Validation Thomas A. Little Ph.D. 2/12/2014 President Thomas A. Little Consulting 12401 N Wildflower Lane Highland, UT 84003 1-925-285-1847 drlittle@dr-tom.com
More informationGMP Advisor The GMP Questions & Answers Guide Version 01 of April 2014
GMP Advisor The GMP Questions & Answers Guide Version 01 of April 2014 Page 1 of 152 About this document Searching for concrete answers to GMP questions is a time-consuming activity. This document is intended
More informationICH Topic S 1 A The Need for Carcinogenicity Studies of Pharmaceuticals. Step 5
European Medicines Agency July 1996 CPMP/ICH/140/95 ICH Topic S 1 A The Need for Carcinogenicity Studies of Pharmaceuticals Step 5 NOTE FOR GUIDANCE ON THE NEED FOR CARCINOGENICITY STUDIES OF PHARMACEUTICALS
More informationINTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE S1A. Current Step 4 version
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE GUIDELINE ON THE NEED FOR CARCINOGENICITY STUDIES
More informationPublic Assessment Report Scientific discussion. Prednisolon Pilum (prednisolone) Asp no: 2013-0498
Public Assessment Report Scientific discussion Prednisolon Pilum (prednisolone) Asp no: 2013-0498 This module reflects the scientific discussion for the approval of Prednisolon Pilum. The procedure was
More informationMHRA GMP Data Integrity Definitions and Guidance for Industry March 2015
MHRA GMP Data Integrity Definitions and Guidance for Industry Introduction: Data integrity is fundamental in a pharmaceutical quality system which ensures that medicines are of the required quality. This
More informationApplication Note. Separation of three monoclonal antibody variants using MCSGP. Summary
Application Note Separation of three monoclonal antibody variants using MCSGP Category Matrix Method Keywords Analytes ID Continuous chromatography, Biochromatography; FPLC Protein A-purified monoclonal
More informationJournal of Chemical and Pharmaceutical Research
Available on line www.jocpr.com Journal of Chemical and Pharmaceutical Research J. Chem. Pharm. Res., 2010, 2(1): 91-99 ISSN No: 0975-7384 A Stability-Indicating RP-LC method for the Determination of Related
More informationPeptide purification strategies
Särö Conference 2009 Peptide purification strategies Ulf Altenhöner Lonza Exclusive Synthesis R&D Outline Introduction Integrated process development Model-based process development Inspiration Conclusions
More informationCommercial Manufacturing - Qualification & Validation-related GMP Deficiencies and Other Lifecycle Considerations
Commercial Manufacturing - Qualification & Validation-related GMP Deficiencies and Other Lifecycle Considerations Kevin O Donnell PhD Market Compliance Manager, IMB PDA / FDA Conference Pharmaceutical
More informationDevelop a Quantitative Analytical Method for low (» 1 ppm) levels of Sulfate
Cantaurus, Vol. 7, 5-8, May 1999 McPherson College Division of Science and Technology Develop a Quantitative Analytical Method for low (» 1 ppm) levels of Sulfate Janet Bowen ABSTRACT Sulfate is used in
More informationC 5. chemical development contract research custom synthesis cgmp API manufacturing commercial production. Welcome to
C 5 chemical development contract research custom synthesis cgmp API manufacturing commercial production Welcome to ChemCon Company profile Company profile ChemCon offers outstanding chemical services
More informationPesticide Analysis by Mass Spectrometry
Pesticide Analysis by Mass Spectrometry Purpose: The purpose of this assignment is to introduce concepts of mass spectrometry (MS) as they pertain to the qualitative and quantitative analysis of organochlorine
More informationEUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY VERSION 7
EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY Health systems and products Medicinal products quality, safety and efficacy Brussels, IMPORTATION OF ACTIVE SUBSTANCES FOR MEDICINAL PRODUCTS
More informationSUCRALOSE. White to off-white, practically odourless crystalline powder
SUCRALOSE Prepared at the 41st JECFA (1993), published in FNP 52 Add 2 (1993). Metals and arsenic specifications revised at the 63rd JECFA (2004). An ADI of 0-15 mg/kg bw was established at the 37th JECFA
More informationThe Automated SPE Assay of Fipronil and Its Metabolites from Bee Pollen.
The Automated SPE Assay of Fipronil and Its Metabolites from Bee Pollen. Mark Crawford Single Presenter Name Abstract With the recent decline in hive bee populations this year the investigation of acaricides
More informationWorking Party on Control of Medicines and Inspections. Final Version of Annex 15 to the EU Guide to Good Manufacturing Practice
EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Single market, regulatory environment, industries under vertical legislation Pharmaceuticals and cosmetics Brussels, July 2001 Working Party on Control
More informationExpectations for Data to Support Clinical Trial Drugs
Expectations for Data to Support Clinical Trial Drugs Presentation to: APEC Advanced Workshop on Review of Drug Development in Clinical Trials Bangkok Thailand Feb 2-6 2009 Willem Stevens Ph.D., Chief
More informationStandard Analytical Methods of Bioactive Metabolitesfrom Lonicera japonica Flower Buds by HPLC-DAD and HPLC-MS/MS
Standard Analytical Methods of Bioactive Metabolitesfrom Lonicera japonica Flower Buds by HPLCDAD and HPLCMS/MS Jongheon Shin College of Pharmacy Seoul National University Summary The standard analytical
More informationGOED VOLUNTARY MONOGRAPH (v. 4)
GOED VOLUNTARY MONOGRAPH (v. 4) Omega-3 EPA Omega-3 DHA Omega-3 EPA & DHA DEFINITION Omega-3 fatty acids, EPA and DHA, consist of the all cis forms of 5, 8, 11, 14, 17-eicosapentaenoic acid and 4, 7, 10,
More informationVolume 2B Notice to Applicants. Medicinal products for human use. Presentation and format of the dossier. Common Technical Document (CTD)
Volume 2B Notice to Applicants Medicinal products for human use Presentation and format of the dossier Common Technical Document (CTD) Introduction Edition June 26 Module 1 Edition May 28 Module 2 Edition
More informationEUDRAGIT E 100, EUDRAGIT E PO and
Technical Information EUDRAGIT E 100, and Specification and Test Methods Ph. Eur. USP/NF JPE Basic Butylated Methacrylate Copolymer Amino Methacrylate Copolymer - NF Aminoalkyl Methacrylate Copolymer E
More informationPROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES: VALIDATION, APPENDIX 7: NON-STERILE PROCESS VALIDATION
April 2013 RESTRICTED 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 PROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES:
More informationABRF 2004 Poster# P55-S Displacement Chromatography Effects Can Cause Highly Selective Sampling of Peptides During Solid Phase Extraction Cleanup
ABRF 2004 Poster# P55-S Displacement Chromatography Effects Can Cause Highly Selective Sampling of Peptides During Solid Phase Extraction Cleanup by Andrew J. Alpert PolyLC Inc./ 9151 Rumsey Road, ste.
More informationIMPURITIES AND ITS IMPORTANCE IN PHARMACY
IMPURITIES AND ITS IMPORTANCE IN PHARMACY S. Lakshmana Prabu 1*, T.N.K. Suriyaprakash 2 1 Department of Pharmaceutical Technology, Anna University-Tiruchirappalli, Tiruchirappalli 620 024. 2 Department
More informationMHRA GMP Data Integrity Definitions and Guidance for Industry January 2015
MHRA GMP Data Integrity Definitions and Guidance for Industry Introduction: Data integrity is fundamental in a pharmaceutical quality system which ensures that medicines are of the required quality. This
More informationEUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL VERSION 4.1
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health systems and products Medicinal products quality, safety and efficacy Brussels, SANCO/D/6/SF/mg/ddg1.d.6(2013) IMPORTATION OF ACTIVE SUBSTANCES
More informationReversed Phase High Presssure Liquid Chromatograhphic Technique for Determination of Sodium Alginate from Oral Suspension
International Journal of PharmTech Research CODEN (USA): IJPRIF ISSN : 0974-4304 Vol.2, No.2, pp 1634-1638, April-June 2010 Reversed Phase High Presssure Liquid Chromatograhphic Technique for Determination
More informationA Grignard reagent formed would deprotonate H of the ethyl alcohol OH.
216 S11-E2 Page 2 Name Key I. (9 points) Answer in the boxes below the following questions for the Grignard reagent C 3 -Mg. (1) (2 points) Is the carbon atom associated with magnesium electrophilic or
More informationUsing Natural Products Application Solution with UNIFI for the Identification of Chemical Ingredients of Green Tea Extract
Using Natural Products Application Solution with UNIFI for the Identification of Chemical Ingredients of Green Tea Extract Lirui Qiao, 1 Rob Lewis, 2 Alex Hooper, 2 James Morphet, 2 Xiaojie Tan, 1 Kate
More informationAnnex 1 WHO good practices for pharmaceutical quality control laboratories
World Health Organization WHO Technical Report Series, No. 957, 2010 Annex 1 WHO good practices for pharmaceutical quality control laboratories General considerations Glossary Part one. Management and
More informationEDQM: 50 YEARS OF LEADERSHIP IN THE QUALITY OF MEDICINES PAVING THE WAY FOR THE FUTURE
EDQM: 50 YEARS OF LEADERSHIP IN THE QUALITY OF MEDICINES PAVING THE WAY FOR THE FUTURE 6-8 October 2014 Strasbourg, France WORKSHOP QUALITY BY DESIGN 1 The Pharmacopoeia and QbD 7 October 2014 Dr. Øyvind
More informationSorbents. [ A] [ A] aq. Strong affinity = large K D. Digital chromatography: all-or. or-nothing LC mechanism to extremes K =
Theory of SPE 1 SPE Nonequilibrium,, exhaustive removal of chemical constituents from a flowing liquid sample via retention on a contained solid sorbent and subsequent recovery of selected constituents
More informationof Biologics Using LC/MS in Compliant Laboratories
Demonstrating Comparability and Consistency of Biologics Using LC/MS in Compliant Laboratories Patrick Boyce Biopharmaceutical Marketing Manager Europe & India Waters 2011 Waters Corporation Overview Challenges
More informationPeptide synthesis, radiolabelling and radiochemical analysis
SUPPLEMENTAL DATA MATERIALS AND METHODS Peptide synthesis, radiolabelling and radiochemical analysis Solid phase synthesis of peptides was carried out on using ABI 433A peptide synthesizer, on a preloaded
More informationMutagenic Impurity Risk Assessment Purge Tool Supporting ICH M7 Control Strategy
Mutagenic Impurity Risk Assessment Purge Tool Supporting ICH M7 Control Strategy Ella Smoraczewska Lhasa Limited Sales Executive Presentation utline Background & Case Study Regulatory Perspective MI Purge
More informationNon-clinical development of biologics
Aurigon Life Science GmbH Non-clinical development of biologics Requirements, challenges and case studies Committed to Life. Sigrid Messemer vet. med. M4 Seminar March 10 th 2014 Aurigon - your full service
More informationVALIDATION OF HPLC METHOD FOR DETERMINATION OF DOCOSAHEXAENOIC ACID (DHA) IN MULIIVITAMIN CAPSULE DIAH WIDOWATI*, ROS SUMARNY, ESTI MUMPUNI
VALIDATION OF HPLC METHOD FOR DETERMINATION OF DOCOSAHEXAENOIC ACID (DHA) IN MULIIVITAMIN CAPSULE DIAH WIDOWATI*, ROS SUMARNY, ESTI MUMPUNI Fakultas Farmasi Universitas Pancasila Jln. Srengseng Sawah,
More informationHow To Use An Acquity Qda Detector
Mass-Directed Isolation of a Synthetic Peptide Using the ACQUITY QDa Detector Jo-Ann M. Jablonski and Andrew J. Aubin Waters Corporation, Milford, MA, USA APPLICATION BENEFITS The ACQUITY QDa Detector
More informationThe Use of Micro Flow LC Coupled to MS/MS in Veterinary Drug Residue Analysis
The Use of Micro Flow LC Coupled to MS/MS in Veterinary Drug Residue Analysis Stephen Lock AB SCIEX Warrington (UK) Overview A rapid, robust, sensitive and specific LC-MS/MS method has been developed for
More information